|2 July 2007||The remit for this guideline was received from the Department of Health and the Welsh Assembly Government in March 2007 as part of the Institute's 14th wave work programme. See below for more information on the Institute's guideline development process.|
|13 September 2007||Commissioning manager changed from Colette Marshall to Christine Sealey|
|14 September 2007||The consultation draft of the guideline is out for consultation with stakeholders. If you wish to comment, you need to do so via one of the registered stakeholder organisations listed above, by the deadline shown.|
|16 October 2007||Consultation on the draft scope is complete and the scope is being modified in the light of comments received. When completed it will be posted on the website. It will define what aspects of care the guideline will cover and to whom it will apply.|
|30 November 2007||List of stakeholders updated.|
|07 May 2008||Scope and final scope comments table added|
|17 February 2009||
The scope defines what aspects of care are covered by the guideline and to whom it applies. Comments that were made by stakeholders during the consultation on the scope can be seen in the scope consultation table. The Guideline Development Group (GDG) oversees the development process. See below for a list of GDG members.
The NCCs may make a focussed call for evidence on specific clinical questions or subquestions, after it has done initial searches. It will be able to make a call at any point during development of the guideline, and stakeholders will usually be given 4 weeks to respond. The NCC will approach all registered stakeholders for this evidence. The NCC may not issue any calls for evidence for a guideline if the Guideline Development Group (GDG) feels it is not necessary. In addition, the NCCs will accept relevant confidential data for consideration by the GDG.
Development of the clinical guideline is under way and is being led by the National Collaborating Centre. The Guideline Development Group meets regularly to oversee and assist the identification, review and synthesis of the evidence, the incorporation of expert consensus opinion and the translation of the evidence into recommendations for practice and audit criteria. Two versions of the guideline are under preparation: a full guideline and a NICE short-form guideline. Please see timescales above for dates of consultation with stakeholders.
|1 April 2009||Responsibility for the development of this guideline has transferred to the National Clinical Guidelines Centre. Key contacts and timelines remain unchanged.|
|3 July 2009||Consultation on the draft of the guideline is complete and the guideline is being modified in the light of comments received.|